Medtronic plc 's MDT brain therapy business gets a boost with the recent FDA approval for the company's latest Deep Brain Stimulation (DBS) Clinician Programmer and ActivaProgramming Application. This ...

Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...

The U.S. FDA approval also includes the Medtronic BrainSense™ Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings.

Medtronic ($MDT) has earned a CE mark for its SureTune2 software. The tech offers physicians patient-specific visualizations which help them to “tune” a patient ...

To help clinicians and patients better optimize the therapy, Medtronic sought user-friendly mobile devices to adjust the programming of DBS implants and to put more control into the patient’s hands.

DUBLIN and SAN JOSE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) ...

The SenSight directional DBS lead system works seamlessly with certain Medtronic neurostimulators, including the recently-approved Percept™ PC neurostimulator.

Medtronic Percept™ DBS therapy is the only sensing-enabled † DBS system available, allowing a physician to use data from a patient’s brain activity to personalize their treatment. Andy says Medtronic ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS programming ...

Medtronic has recalled the auto-registration feature in the StealthStation deep brain stimulation (DBS) software because of inaccuracies during DBS procedures, according to a notice on the US Food ...